ReviewPeerJ2026
Significance of neuroendocrine systems and the gut-brain axis (GBA) in the regulation of obesity.
Review in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is a major global public health issue due to its high morbidity and mortality rates, with its prevalence increasing annually. According to World Health Organization (WHO) estimates, the global population of individuals with obesity has doubled from 1990 to 2022, with over 650 million adults with obesity experiencing metabolic abnormalities such as dyslipidemia, insulin resistance, diabetes, and cardiovascular diseases. Various approaches have been used to treat or prevent obesity including lifestyle interventions, surgery, and pharmacological therapies aimed at reducing energy absorption and increasing energy expenditure. However, these methods do not significantly reduce energy stored in adipose tissues. The conversion of white adipose tissue (WAT) to brown adipose tissue (BAT) presents a promising therapeutic target for obesity treatment. Notably, there is a substantial loss of BAT in individuals with obesity. Conversely, increased BAT is associated with a lower body mass index (BMI), younger age, lower glucose levels, and a decreased incidence of cardiometabolic diseases. Research indicates that BAT formation is modulated by neuro endocrine systems, suggesting a promising therapeutic strategy for obesity prevention and treatment by targeting these systems. In this review, we first discuss the regulation and signaling pathways of neuroendocrine systems involved in energy balance. We then explore the molecular and cellular mechanisms underlying the onset and pathogenesis of obesity and their relationship with neuroendocrine systems. In particular, we summarize the role of the gut-brain axis (GBA) in obesity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.